Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Estimates By $0.01 EPS

Spero Therapeutics (NASDAQ:SPRO) issued its quarterly earnings data on Wednesday. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01, FiscalAI reports. Spero Therapeutics had a return on equity of 16.00% and a net margin of 24.90%.

Here are the key takeaways from Spero Therapeutics’ conference call:

• Utebzi received FDA approval as the first and only oral carbapenem in the U.S. for complicated urinary tract infections, with GSK expecting a U.S. launch in the second half of 2026.
• Spero in-licensed worldwide rights outside Greater China to SP001, a CD40 ligand-targeting antibody for immune-mediated diseases, and plans to begin a Phase II IgG4-related disease trial in the second quarter of 2027.
• The company secured $105 million in non-dilutive, non-recourse royalty financing backed by future Utebzi milestone and royalty payments, extending its expected cash runway into the second half of 2029.
• Second-quarter revenue fell to zero from $14.2 million a year earlier as prior collaboration and government-award funding had been fully recognized; net loss widened to $9.6 million from $1.7 million.

Spero Therapeutics Trading Up 4.2%

SPRO opened at $1.24 on Friday. Spero Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.08. The company has a market cap of $71.80 million, a PE ratio of 11.27 and a beta of 1.55. The company has a 50 day moving average of $1.87 and a 200 day moving average of $2.28.

Analyst Ratings Changes

Several analysts have recently issued reports on SPRO shares. Weiss Ratings upgraded shares of Spero Therapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday. Wall Street Zen downgraded Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Hedge Funds Weigh In On Spero Therapeutics

A number of large investors have recently modified their holdings of the company. Invesco Ltd. bought a new position in Spero Therapeutics in the 2nd quarter valued at $43,000. State Street Corp lifted its holdings in shares of Spero Therapeutics by 10.1% in the 4th quarter. State Street Corp now owns 210,151 shares of the company’s stock worth $490,000 after acquiring an additional 19,200 shares during the last quarter. Millennium Management LLC bought a new stake in Spero Therapeutics in the fourth quarter worth $56,000. Dimensional Fund Advisors LP purchased a new stake in Spero Therapeutics during the 3rd quarter valued at about $55,000. Finally, XTX Topco Ltd bought a new stake in Spero Therapeutics in the 2nd quarter worth $100,000. 25.60% of the stock is currently owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug?resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram?negative pathogens.